215 related articles for article (PubMed ID: 28939121)
1. Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment.
Ali I; Lee J; Go A; Choi G; Lee K
Bioorg Med Chem Lett; 2017 Oct; 27(20):4606-4613. PubMed ID: 28939121
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of dihydroquinoxalinone derivatives as BRD4 inhibitors.
Yang Y; Zhao L; Xu B; Yang L; Zhang J; Zhang H; Zhou J
Bioorg Chem; 2016 Oct; 68():236-44. PubMed ID: 27580186
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.
Xue X; Zhang Y; Liu Z; Song M; Xing Y; Xiang Q; Wang Z; Tu Z; Zhou Y; Ding K; Xu Y
J Med Chem; 2016 Feb; 59(4):1565-79. PubMed ID: 26731490
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.
Bennett MJ; Wu Y; Boloor A; Matuszkiewicz J; O'Connell SM; Shi L; Stansfield RK; Del Rosario JR; Veal JM; Hosfield DJ; Xu J; Kaldor SW; Stafford JA; Betancort JM
Bioorg Med Chem Lett; 2018 Jun; 28(10):1811-1816. PubMed ID: 29657099
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy.
Kong B; Zhu Z; Li H; Hong Q; Wang C; Ma Y; Zheng W; Jiang F; Zhang Z; Ran T; Bian Y; Yang N; Lu T; Zhu J; Tang W; Chen Y
Eur J Med Chem; 2022 Jan; 227():113953. PubMed ID: 34731760
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design.
Duffy BC; Liu S; Martin GS; Wang R; Hsia MM; Zhao H; Guo C; Ellis M; Quinn JF; Kharenko OA; Norek K; Gesner EM; Young PR; McLure KG; Wagner GS; Lakshminarasimhan D; White A; Suto RK; Hansen HC; Kitchen DB
Bioorg Med Chem Lett; 2015 Jul; 25(14):2818-23. PubMed ID: 26022843
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of novel 4,4-difluoro-1-methyl-N, 6-diphenyl-5, 6-dihydro-4H-pyrimido [4, 5-b] [1, 2, 4] triazolo [4, 3-d] [1, 4] diazepin-8-amine derivatives as potential BRD4 inhibitors.
Li J; Zhang W; Qiu Q; Zhou D; Feng Z; Tong Z; Wei J; Huang W; Li J; Qian H; Shi W
Chem Biol Drug Des; 2021 May; 97(5):1117-1128. PubMed ID: 33638254
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues.
Jiang H; Xing J; Wang C; Zhang H; Yue L; Wan X; Chen W; Ding H; Xie Y; Tao H; Chen Z; Jiang H; Chen K; Chen S; Zheng M; Zhang Y; Luo C
Org Biomol Chem; 2017 Nov; 15(44):9352-9361. PubMed ID: 29087414
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors.
Feng Y; Xiao S; Chen Y; Jiang H; Liu N; Luo C; Chen S; Chen H
Eur J Med Chem; 2018 May; 152():264-273. PubMed ID: 29730189
[TBL] [Abstract][Full Text] [Related]
13. Methylpyrrole inhibitors of BET bromodomains.
Hasvold LA; Sheppard GS; Wang L; Fidanze SD; Liu D; Pratt JK; Mantei RA; Wada CK; Hubbard R; Shen Y; Lin X; Huang X; Warder SE; Wilcox D; Li L; Buchanan FG; Smithee L; Albert DH; Magoc TJ; Park CH; Petros AM; Panchal SC; Sun C; Kovar P; Soni NB; Elmore SW; Kati WM; McDaniel KF
Bioorg Med Chem Lett; 2017 May; 27(10):2225-2233. PubMed ID: 28268136
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel coumarin derivatives as potent and orally bioavailable BRD4 inhibitors based on scaffold hopping.
Zhang Z; Gu L; Wang B; Huang W; Zhang Y; Ma Z; Zeng S; Shen Z
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):808-817. PubMed ID: 30879350
[TBL] [Abstract][Full Text] [Related]
15. JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms.
Choi SK; Hong SH; Kim HS; Shin CY; Nam SW; Choi WS; Han JW; You JS
Oncol Rep; 2016 Feb; 35(2):1186-94. PubMed ID: 26573731
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
[TBL] [Abstract][Full Text] [Related]
17. [1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains.
Fedorov O; Lingard H; Wells C; Monteiro OP; Picaud S; Keates T; Yapp C; Philpott M; Martin SJ; Felletar I; Marsden BD; Filippakopoulos P; Müller S; Knapp S; Brennan PE
J Med Chem; 2014 Jan; 57(2):462-76. PubMed ID: 24313754
[TBL] [Abstract][Full Text] [Related]
18. Investigation of novel ligand targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery: complete pharmacophore approach.
Shanmugam V; Muthukrishnan S
J Biomol Struct Dyn; 2023; 41(23):14524-14539. PubMed ID: 36841551
[TBL] [Abstract][Full Text] [Related]
19. Targeting BET bromodomains for cancer treatment.
Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel 2-piperidinol-3-(arylsulfonyl)quinoxalines as phosphoinositide 3-kinase α (PI3Kα) inhibitors.
Wu P; Su Y; Liu X; Yang B; He Q; Hu Y
Bioorg Med Chem; 2012 May; 20(9):2837-44. PubMed ID: 22480851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
